SingVax was set up in 2004, as Singapore's first vaccine development company. SingVax focuses on developing prophylactic vaccines for infectious diseases of relevance to the Asia Pacific region and aims to be the partner of choice for vaccine companies seeking to access the Asia Pacific vaccine market.
Worldwide, infectious diseases result in an estimated 13 million deaths per annum, ranking as the second biggest killer. With the challenge of emerging and re-emerging infectious diseases, there is a significant need for improved and novel vaccines. |
Together with the growing demand for better health care, globalisation, urbanisation and ineffectiveness of current treatments, there is a substantial medical need for effective vaccines. The vaccine market is estimated to grow at a CAGR of 14%, which is largely driven by prophylactic vaccines. Understanding the growing market demand for effective vaccines, SingVax has adopted a product-focused approach to build a valuable and internationally-competitive vaccine company. |